Celcuity (CELC)

Executive Summary

Celcuity is a clinical-stage biotechnology company developing targeted therapies for cancers driven by the PAM (PI3K/AKT/mTOR) pathway. Its lead candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor designed to comprehensively block this critical signaling network, offering a promising approach for solid tumors such as breast and prostate cancers. The company's proprietary technology aims to improve outcomes by addressing resistance mechanisms commonly seen with single-agent inhibitors. In 2025, Celcuity reported encouraging Phase 1b/2 data for gedatolisib in combination with endocrine therapy in HR+/HER2- advanced breast cancer, showing meaningful clinical activity and manageable safety. The company is now advancing gedatolisib into pivotal trials, with a focus on hormone receptor-positive breast cancer and metastatic castration-resistant prostate cancer (mCRPC). With a strong scientific rationale and early clinical validation, Celcuity represents a high-risk, high-reward opportunity in oncology drug development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data for gedatolisib plus palbociclib and letrozole in first-line HR+/HER2- breast cancer60% success
• Q1 2027Initiation of Phase 3 trial for gedatolisib in mCRPC70% success
• TBDPotential partnership or licensing deal for gedatolisib outside North America40% success